MENU

CRP and SAA Tests: WHO Target Product Profile for TB Screening

medRxiv
Overview
Near point-of-care fluorescence immunoassay (NPOCT-FIA) for C-reactive protein (CRP) and serum amyloid A (SAA) met WHO target product profile criteria for tuberculosis (TB) triage screening. Combined use of these biomarkers achieved 100.0% sensitivity and 83.3% specificity in identifying confirmed TB.
In Depth

Key Findings

The study demonstrates that SAA and CRP exhibit excellent diagnostic performance for identifying confirmed tuberculosis (TB). When combined, CRP and SAA achieved a sensitivity of 100.0% and a specificity of 83.3%. Individually, SAA showed an AUC of 0.961 (sensitivity 96.5%, specificity 88.6% at a cut-off > 31.0 mg/L), and CRP showed an AUC of 0.953 (sensitivity 96.5%, specificity 86.0% at a cut-off 21.3 mg/L). In contrast, interferon gamma-induced protein 10 (IP-10) showed poor discrimination with an AUC of 0.545.

Technical Details

This cross-sectional diagnostic study utilized stored archived serum samples from three distinct subject groups: bacteriology confirmed symptomatic TB (n=57), probable TB (n=56), and healthy controls (n=60). The researchers employed two different measurement methodologies:

  • NPOCT-FIA: Used to measure concentrations of C-reactive protein (CRP) and serum amyloid A (SAA).
  • ELISA: Used to measure interferon gamma-induced protein 10 (IP-10).

The diagnostic performance was evaluated using Receiver operating characteristic (ROC) analysis to determine the AUC and optimal cut-off values for each biomarker.

Background & Context

TB eradication strategies in countries with a high burden of the disease require screening tools that are affordable, scalable, and accessible. The research focused on evaluating whether these specific biomarkers could serve as effective triage tools to streamline the identification of TB patients.

Significance & Outlook

The results indicate that SAA and CRP meet the WHO target product profile criteria for TB triage screening. By providing high sensitivity and specificity through near point-of-care testing, these biomarkers offer a potential pathway for scalable screening in high-burden regions, whereas IP-10 was found to be an ineffective discriminator in this specific diagnostic context.

Source: https://doi.org/10.64898/2026.11.10.26367691

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC